Zevra Therapeutics faces critical revenue risk tied to single rare disease drug
Zevra Therapeutics, a commercial-stage biopharmaceutical company, depends on MIPLYFFA approval for financial viability. Any regulatory action against the rare disease treatment could threaten the company's survival. The concentration risk reflects broader challenges facing single-product biotech firms.
ViaNews Editorial Team (Finance)•